nach oben

Erschienen in:

08.02.2022

Cardiorenal syndrome: long road between kidney and heart

verfasst von: Carolina Victoria Cruz Junho, Mayra Trentin-Sonoda, Karine Panico, Raquel Silva Neres dos Santos, Mariana Vieira Abrahão, Imara Caridad Stable Vernier, Cristina Ribas Fürstenau, Marcela Sorelli Carneiro-Ramos

Erschienen in: Heart Failure Reviews | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Almost 200 years ago, the first evidence described by Robert Bright (1836) showed the strong interaction between the kidneys and heart and, since then, the scientific community has dedicated itself to better understanding the mechanisms involved in the kidney–heart relationship, known in recent decades as cardiorenal syndrome (CRS). This syndrome includes a wide clinical variety that affects the kidneys and heart, in an acute or chronic manner. Moreover, it is well established in the literature that the immune system, the sympathetic nervous system, the renin–angiotensin–aldosterone, and the oxidative stress actively play a strong role in the cellular and molecular processes present in CRS. More recently, uremic molecules and epigenetic factors have been also shown to be key mediators in the development of syndrome. The present review intends to present the state of the art regarding CRS and to show the paths known, until now, in the long road between the kidneys and heart.

Bright R (1836) Cases and observations illustrative of renal disease, accompanied with the secretion of albuminous urine. Medico-chirurgical Rev 25:23–35

Hatamizadeh P, Fonarow GC, Budoff MJ et al (2013) Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9:99–111. https://doi.org/10.1038/nrneph.2012.279CrossRefPubMed

Ronco C, McCullough P, Anker SD et al (2010) Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 31:703–711. https://doi.org/10.1093/eurheartj/ehp507CrossRefPubMed

Savira F, Magaye R, Liew D et al (2020) Cardiorenal syndrome: multi-organ dysfunction involving the heart, kidney and vasculature. Br J Pharmacol 177:2906–2922. https://doi.org/10.1111/bph.15065CrossRefPubMedPubMedCentral

Doi K, Noiri E (2016) Mitochondrial dysfunction in cardiorenal syndrome. Antioxidants Redox Signal 25:200–207. https://doi.org/10.1089/ars.2016.6654CrossRef

Raina R, Nair N, Chakraborty R et al (2020) An update on the pathophysiology and treatment of cardiorenal syndrome. Cardiol Res 11:76–88. https://doi.org/10.14740/cr955

Di Lullo L, Bellasi A, Barbera V et al (2017) Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate. Indian Heart J 69:255–265. https://doi.org/10.1016/j.ihj.2017.01.005CrossRefPubMedPubMedCentral

Clementi A, Virzì GM, Battaglia GG, Ronco C (2019) Neurohormonal, endocrine, and immune dysregulation and inflammation in cardiorenal syndrome. Cardiorenal Med 9:265–273. https://doi.org/10.1159/000500715CrossRefPubMed

Di Lullo L, House A, Gorini A et al (2015) Chronic kidney disease and cardiovascular complications. Heart Fail Rev 20:259–272. https://doi.org/10.1007/s10741-014-9460-9CrossRefPubMed

10.

Navarro-García JA, Fernández-Velasco M, Delgado C et al (2018) PTH, vitamin D, and the FGF-23–klotho axis and heart: Going beyond the confines of nephrology. Eur J Clin Invest 48

11.

Falconi CA, Junho CVC, Fogaça-Ruiz F et al (2021) Uremic toxins: an alarming danger concerning the cardiovascular system. Front Physiol 12. https://doi.org/10.3389/fphys.2021.686249

12.

Colombo PC, Ganda A, Lin J et al (2012) Inflammatory activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17:177–190. https://doi.org/10.1007/s10741-011-9261-3CrossRefPubMed

13.

Mehta RL, Bouchard J, Soroko SB et al (2011) Sepsis as a cause and consequence of acute kidney injury: program to improve care in acute renal disease. Intensive Care Med 37:241–248. https://doi.org/10.1007/s00134-010-2089-9CrossRefPubMed

14.

Ronco C, Di Lullo L (2014) Cardiorenal syndrome Heart Fail Clin 10:251–280CrossRef

15.

Adams PL, Adams FF, Bell PD, Navar LG (1980) Impaired renal blood flow autoregulation in ischemic acute renal failure. Kidney Int 18:68–76. https://doi.org/10.1038/ki.1980.111CrossRefPubMed

16.

Matthys E, Patton MK, Osgood RW et al (1983) Alterations in vascular function and morphology in acute ischemic renal failure. Kidney Int 23:717–724. https://doi.org/10.1038/ki.1983.84CrossRefPubMed

17.

Conger JD, Robinette JB, Hammond WS (1991) Differences in vascular reactivity in models of ischemic acute renal failure. Kidney Int 39:1087–1097. https://doi.org/10.1038/ki.1991.138CrossRefPubMed

18.

Yang C-C, Chen Y-T, Chen C-H et al (2019) The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet. Biomed Pharmacother 116:108954. https://doi.org/10.1016/j.biopha.2019.108954CrossRefPubMed

19.

Mohammadi M, Najafi H, Mohamadi Yarijani Z et al (2020) Protective effect of piperine in ischemia-reperfusion induced acute kidney injury through inhibition of inflammation and oxidative stress. J Tradit Complement Med 10:570–576. https://doi.org/10.1016/j.jtcme.2019.07.002CrossRefPubMed

20.

Casas A, Mallén A, Blasco-Lucas A et al (2020) Chronic kidney disease-associated inflammation increases the risks of acute kidney injury and mortality after cardiac surgery. Int J Mol Sci 21:9689. https://doi.org/10.3390/ijms21249689CrossRefPubMedCentral

21.

Ueda S, Ayano Y, Yano S et al (1981) Changes in vascular reactivity in rats with experimental renal insufficiency. Arch Int Pharmacodyn Ther 253:257–265PubMed

22.

Amann K (1995) Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 8:409–417. https://doi.org/10.1016/0895-7061(94)00248-ACrossRefPubMed

23.

Nesher N, Frolkis I, Schwartz D et al (2014) L-arginine improves endothelial function, independently of arginine uptake, in aortas from chronic renal failure female rats. Am J Physiol Physiol 306:F449–F456. https://doi.org/10.1152/ajprenal.00457.2013CrossRef

24.

Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM (1992) In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19:692–696. https://doi.org/10.1161/01.HYP.19.6.692CrossRefPubMed

25.

Dzau VJ, Colucci WS, Williams GH et al (1980) Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 302:1373–1379. https://doi.org/10.1056/NEJM198006193022501CrossRefPubMed

26.

Turini G, Brunner H, Gribic M et al (1979) Improvement of chronic congestive heart-failure by oral captopril. Lancet 313:1213–1215. https://doi.org/10.1016/S0140-6736(79)91897-XCrossRef

27.

Nio Y, Matsubara H, Murasawa S et al (1995) Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 95:46–54. https://doi.org/10.1172/JCI117675CrossRefPubMedPubMedCentral

28.

Zhu Y-C, Zhu Y-Z, Gohlke P et al (1997) Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol 80:110A-117A. https://doi.org/10.1016/S0002-9149(97)00465-7CrossRefPubMed

29.

Wu J, You J, Wang S et al (2014) Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart. Circ J 78:1283–1289. https://doi.org/10.1253/circj.CJ-14-0470CrossRefPubMed

30.

Carneiro-Ramos MS, Diniz GP, Nadu AP et al (2010) Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol 105:325–335. https://doi.org/10.1007/s00395-010-0089-0CrossRefPubMed

31.

Diniz GP, Carneiro-Ramos MS, Barreto-Chaves MLM (2009) Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3β/mTOR signaling pathway. Basic Res Cardiol 104:653–667. https://doi.org/10.1007/s00395-009-0043-1CrossRefPubMed

32.

Vignier N, Le Corvoisier P, Blard C et al (2014) AT1 blockade abolishes left ventricular hypertrophy in heterozygous cMyBP-C null mice: role of FHL1. Fundam Clin Pharmacol 28:249–256. https://doi.org/10.1111/fcp.12031CrossRefPubMed

33.

Weber KT (2001) Aldosterone in congestive heart failure. N Engl J Med 345:1689–1697. https://doi.org/10.1056/NEJMra000050CrossRefPubMed

34.

Dai W, Kloner RA (2011) Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction. Postgrad Med 123:49–55. https://doi.org/10.3810/pgm.2011.03.2263CrossRefPubMed

35.

Panico K, Abrahão MV, Trentin-Sonoda M et al (2019) Cardiac inflammation after ischemia-reperfusion of the kidney: Role of the sympathetic nervous system and the renin-angiotensin system. Cell Physiol Biochem 53:587–605. https://doi.org/10.33594/000000159

36.

Zhong J, Guo D, Chen CB et al (2011) Prevention of angiotensin II–mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57:314–322. https://doi.org/10.1161/HYPERTENSIONAHA.110.164244CrossRefPubMed

37.

Zhuo JL, Li XC (2011) New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides 32:1551–1565. https://doi.org/10.1016/j.peptides.2011.05.012CrossRefPubMedPubMedCentral

38.

Santos RAS, Oudit GY, Verano-Braga T et al (2019) The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Circ Physiol 316:H958–H970. https://doi.org/10.1152/ajpheart.00723.2018CrossRef

39.

Patel VB, Zhong J-C, Grant MB, Oudit GY (2016) Role of the ACE2/angiotensin 1–7 axis of the renin–angiotensin system in heart failure. Circ Res 118:1313–1326. https://doi.org/10.1161/CIRCRESAHA.116.307708CrossRefPubMedPubMedCentral

40.

Amraei R, Rahimi N (2020) COVID-19, renin-angiotensin system and endothelial dysfunction. Cells 9:1652. https://doi.org/10.3390/cells9071652CrossRefPubMedCentral

41.

Pecly IMD, Azevedo RB, Muxfeldt ES et al (2021) A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. Brazilian J Nephrol. https://doi.org/10.1590/2175-8239-jbn-2020-0204CrossRef

42.

Carter JR, Goldstein DS (2014) Sympathoneural and adrenomedullary responses to mental stress. Comprehensive physiology. John Wiley & Sons Inc, Hoboken, NJ, USA, pp 119–146CrossRef

43.

Burnstock G (2013) Cotransmission in the autonomic nervous system. Handbook Clin Neurol 23–35

44.

Park J (2012) Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system. Cardiol Res Pract 2012:1–8. https://doi.org/10.1155/2012/319432CrossRef

45.

Trentin-Sonoda M, Da Silva RC, Kmit FV et al (2015) Knockout of toll-like receptors 2 and 4 prevents renal ischemia-reperfusion-induced cardiac hypertrophy in mice. PLoS ONE 10:1–21. https://doi.org/10.1371/journal.pone.0139350CrossRef

46.

Alarcon MML, Trentin-Sonoda M, Panico K et al (2019) Cardiac arrhythmias after renal I/R depend on IL-1β. J Mol Cell Cardiol 131:101–111. https://doi.org/10.1016/j.yjmcc.2019.04.025CrossRefPubMed

47.

Veiga AC, Milanez MIO, Campos RR et al (2021) The involvement of renal afferents in the maintenance of cardiorenal diseases. Am J Physiol Integr Comp Physiol 320:R88–R93. https://doi.org/10.1152/ajpregu.00225.2020CrossRef

48.

Ramchandra R, Xing DT, Matear M et al (2019) Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure. Am J Physiol Integr Comp Physiol 317:R386–R396. https://doi.org/10.1152/ajpregu.00026.2019CrossRef

49.

Fujiu K, Shibata M, Nakayama Y et al (2017) A heart–brain–kidney network controls adaptation to cardiac stress through tissue macrophage activation. Nat Med 23:611–622. https://doi.org/10.1038/nm.4326CrossRefPubMed

50.

Jougasaki M, Tachibana I, Luchner A et al (2000) Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 101:14–17. https://doi.org/10.1161/01.CIR.101.1.14CrossRefPubMed

51.

Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES (2000) The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52:595–638PubMed

52.

Crowley SD, Gurley SB, Herrera MJ et al (2006) Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci 103:17985–17990. https://doi.org/10.1073/pnas.0605545103CrossRefPubMedPubMedCentral

53.

Stupin A, Drenjancevic I, Rasic L et al (2017) A cross-talk between the renin-angiotensin and adrenergic systems in cardiovascular health and disease. Eur Med J 1:90–107

54.

Chaar LJ, Alves TP, Batista Junior AM, Michelini LC (2015) Early training-induced reduction of angiotensinogen in autonomic areas—the main effect of exercise on brain renin-angiotensin system in hypertensive rats. PLoS ONE 10:e0137395. https://doi.org/10.1371/journal.pone.0137395CrossRefPubMedPubMedCentral

55.

Gueguen C, Jackson KL, Marques FZ et al (2019) Renal nerves contribute to hypertension in Schlager BPH/2J mice. Hypertens Res 42:306–318. https://doi.org/10.1038/s41440-018-0147-9CrossRefPubMed

56.

Vieira-Rocha MS, Rodríguez-Rodríguez P, Sousa JB et al (2019) Vascular angiotensin AT1 receptor neuromodulation in fetal programming of hypertension. Vascul Pharmacol 117:27–34. https://doi.org/10.1016/j.vph.2018.10.003CrossRefPubMed

57.

Chen B, Frangogiannis NG (2017) Immune cells in repair of the infarcted myocardium. Microcirculation 24:e12305. https://doi.org/10.1111/micc.12305CrossRef

58.

Clementi A, Virzì GM, Brocca A et al (2015) Advances in the pathogenesis of cardiorenal syndrome type 3. Oxid Med Cell Longev 2015:1–8. https://doi.org/10.1155/2015/148082CrossRef

59.

Ayoub KF, Pothineni NVK, Rutland J et al (2017) Immunity, inflammation, and oxidative stress in heart failure: emerging molecular targets. Cardiovasc Drugs Ther 31:593–608. https://doi.org/10.1007/s10557-017-6752-zCrossRefPubMed

60.

Jo E-K, Kim JK, Shin D-M, Sasakawa C (2016) Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 13:148–159. https://doi.org/10.1038/cmi.2015.95CrossRefPubMed

61.

Monnerat G, Alarcón ML, Vasconcellos LR et al (2016) Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat Commun 7:13344. https://doi.org/10.1038/ncomms13344CrossRefPubMedPubMedCentral

62.

Pullen AB, Jadapalli JK, Rhourri-Frih B, Halade GV (2020) Re-evaluating the causes and consequences of non-resolving inflammation in chronic cardiovascular disease. Heart Fail Rev 25:381–391. https://doi.org/10.1007/s10741-019-09817-xCrossRefPubMedPubMedCentral

63.

Carrillo-Salinas FJ, Ngwenyama N, Anastasiou M et al (2019) Heart inflammation. Am J Pathol 189:1482–1494. https://doi.org/10.1016/j.ajpath.2019.04.009CrossRefPubMedPubMedCentral

64.

Adamo L, Rocha-Resende C, Prabhu SD, Mann DL (2020) Reappraising the role of inflammation in heart failure. Nat Rev Cardiol 17:269–285. https://doi.org/10.1038/s41569-019-0315-xCrossRefPubMed

65.

Patel B, Ismahil MA, Hamid T et al (2017) Mononuclear phagocytes are dispensable for cardiac remodeling in established pressure-overload heart failure. PLoS ONE 12:e0170781. https://doi.org/10.1371/journal.pone.0170781CrossRefPubMedPubMedCentral

66.

Schiattarella GG, Sequeira V, Ameri P (2020) Distinctive patterns of inflammation across the heart failure syndrome. Heart Fail Rev. https://doi.org/10.1007/s10741-020-09949-5CrossRef

67.

Virzì GM, Zhang J, Nalesso F et al (2018) The role of dendritic and endothelial cells in cardiorenal syndrome. Cardiorenal Med 8:92–104. https://doi.org/10.1159/000485937CrossRefPubMedPubMedCentral

68.

Ronco C, Di Lullo L (2018) Cardiorenal acute kidney injury: epidemiology, presentation, causes, pathophysiology, and treatment. core concepts in acute kidney injury. Springer, US, New York, NY, pp 257–269CrossRef

69.

Castillo-Rodríguez E, Pizarro-Sánchez S, Sanz AB et al (2017) Inflammatory cytokines as uremic toxins: “ni son todos los queestan, ni estan todos los que son” Toxins (Basel) 9. https://doi.org/10.3390/toxins9040114

70.

Junho CVC, Azevedo CAB, da Cunha RS et al (2021) Heat shock proteins: connectors between heart and kidney. Cells 10:1939. https://doi.org/10.3390/cells10081939CrossRefPubMedPubMedCentral

71.

Ortega-Hernández J, Springall R, Sánchez-Muñoz F et al (2017) Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function. BMC Cardiovasc Disord 17:202. https://doi.org/10.1186/s12872-017-0640-0CrossRefPubMedPubMedCentral

72.

Machado Rocha Ribeiro S, Humberto de Queiroz J, do Carmo Gouveia Peluzio M et al (2005) The formation and the effects of the reactive oxygen species in biological media. Biosci J 21:133–149

73.

Pruchniak MP, Araźna M, Demkc U (2016) Biochemistry of oxidative stress. Advances in experimental medicine and biology. Springer, New York LLC, pp 9–19

74.

Siti HN, Kamisah Y, Kamsiah J (2015) The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol 71:40–56CrossRef

75.

Duann P, Lin PH (2017) Mitochondria damage and kidney disease. Advances in experimental medicine and biology. Springer, New York LLC, pp 529–551

76.

Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS (2016) Oxidant mechanisms in renal injury and disease. Antioxidants Redox Signal 25:119–146CrossRef

77.

Thomas SR, Witting PK, Drummond GR (2008) Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxidants Redox Signal 10:1713–1765CrossRef

78.

Aydinoz S, Uzun G, Cermik H et al (2007) Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail 29:257–263. https://doi.org/10.1080/08860220601166487CrossRefPubMed

79.

Jha JC, Banal C, Chow BSM et al (2016) Diabetes and kidney disease: role of oxidative stress. Antioxidants Redox Signal 25:657–684CrossRef

80.

Choi EK, Jung H, Kwak KH et al (2017) Inhibition of oxidative stress in renal ischemia-reperfusion injury. Anesth Analg 124:204–213. https://doi.org/10.1213/ANE.0000000000001565CrossRefPubMed

81.

Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Ren Physiol 298. https://doi.org/10.1152/ajprenal.00421.2009

82.

Lee DY, Wauquier F, Eid AA et al (2013) Nox4 NADPH oxidase mediates peroxynitrite-dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: Role of mitochondrial reactive oxygen species. J Biol Chem 288:28668–28686. https://doi.org/10.1074/jbc.M113.470971CrossRefPubMedPubMedCentral

83.

Kang SJ, You A, Kwak MK (2011) Suppression of Nrf2 signaling by angiotensin II in murine renal epithelial cells. Arch Pharm Res 34:829–836. https://doi.org/10.1007/s12272-011-0517-1CrossRefPubMed

84.

Rababa’h AM, Guillory AN, Mustafa R, Hijjawi T, (2018) Oxidative stress and cardiac remodeling: an updated edge. Curr Cardiol Rev 14:53–59. https://doi.org/10.2174/1573403x14666180111145207CrossRef

85.

Hamilton CA, Miller WH, Al-Benna S et al (2004) Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci 106:219–234CrossRef

86.

Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81:449–456CrossRef

87.

Siwik DA, Pagano PJ, Colucci WS (2001) Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280. https://doi.org/10.1152/ajpcell.2001.280.1.c53

88.

Liu Y, Lei S, Gao X et al (2012) PKCβ inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfuntion in rats with streptozotocin-induced diabetes. Clin Sci 122:161–173. https://doi.org/10.1042/CS20110176CrossRef

89.

Looi YH, Grieve DJ, Siva A et al (2008) Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 51:319–325. https://doi.org/10.1161/HYPERTENSIONAHA.107.101980CrossRefPubMed

90.

Giam B, Kaye DM, Rajapakse NW (2016) Role of renal oxidative stress in the pathogenesis of the cardiorenal syndrome. Hear Lung Circ 25:874–880CrossRef

91.

Boaz M, Smetana S, Weinstein T et al (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213–1218. https://doi.org/10.1016/S0140-6736(00)02783-5CrossRefPubMed

92.

Caio-Silva W, da Silva DD, Junho CVC et al (2020) Characterization of the oxidative stress in renal ischemia/reperfusion-induced cardiorenal syndrome type 3. Biomed Res Int 2020:1605358. https://doi.org/10.1155/2020/1605358CrossRefPubMedPubMedCentral

93.

Glassock RJ (2008) Uremic toxins: what are they? An integrated overview of pathobiology and classification. J Ren Nutr 18:2–6. https://doi.org/10.1053/j.jrn.2007.10.003CrossRefPubMed

94.

Stinghen AEMEM, Gonçalves SMM, Martines EGG et al (2009) Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron - Clin Pract 111:c117–c126. https://doi.org/10.1159/000191205CrossRefPubMed

95.

Gryp T, Vanholder R, Vaneechoutte M, Glorieux G (2017) p-Cresyl Sulfate. Toxins (Basel) 9:52. https://doi.org/10.3390/toxins9020052CrossRef

96.

Barreto FC, Stinghen AEM, de Oliveira RB et al (2014) The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. J Bras Nefrol 36:221–235. https://doi.org/10.5935/0101-2800.20140033CrossRefPubMed

97.

Lekawanvijit S, Krum H (2015) Cardiorenal syndrome: role of protein-bound uremic toxins. J Ren Nutr 25:149–154. https://doi.org/10.1053/j.jrn.2014.10.009CrossRefPubMed

98.

Tamariz L, Hernandez F, Bush A et al (2014) Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Hear Rhythm 11:1102–1108. https://doi.org/10.1016/j.hrthm.2014.04.003CrossRef

99.

Chaudhary K, Malhotra K, Sowers J, Aroor A (2013) Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome. CardioRenal Med 3:208–220. https://doi.org/10.1159/000355405CrossRefPubMedPubMedCentral

100.

Dhingra R, Gona P, Benjamin EJ et al (2010) Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 12:812–818. https://doi.org/10.1093/eurjhf/hfq106CrossRefPubMedPubMedCentral

101.

Cancela AL, Santos RD, Titan SM et al (2012) Phosphorus is associated with coronary artery disease in patients with preserved renal function. PLoS ONE 7:e36883. https://doi.org/10.1371/journal.pone.0036883CrossRefPubMedPubMedCentral

102.

Dhingra R (2007) Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 167:879. https://doi.org/10.1001/archinte.167.9.879CrossRefPubMed

103.

Tonelli M, Sacks F, Pfeffer M et al (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112:2627–2633. https://doi.org/10.1161/CIRCULATIONAHA.105.553198CrossRefPubMed

104.

Edmonston D, Wolf M (2020) FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol 16:7–19CrossRef

105.

Faul C, Amaral AP, Oskouei B et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408. https://doi.org/10.1172/JCI46122CrossRefPubMedPubMedCentral

106.

Navarro-García JA, Delgado C, Fernández-Velasco M et al (2019) Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. Nephrol Dial Transplant 34:1864–1875. https://doi.org/10.1093/ndt/gfy392CrossRefPubMed

107.

Storino GF, Moraes C, Saldanha J, Mafra D (2015) Cardiovascular mortality in chronic kidney patients: the role of uremic toxins. Int J Cardiovasc Sci 28. https://doi.org/10.5935/2359-4802.20150047

108.

Lekawanvijit S (2018) Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome. Toxins (Basel) 10:352. https://doi.org/10.3390/toxins10090352CrossRef

109.

Huang SY, Chen YA, Chen SA et al (2016) Uremic toxins-novel arrhythmogenic factor in chronic kidney disease-related atrial fibrillation. Acta Cardiol Sin 32:259–264. https://doi.org/10.6515/ACS20151116ACrossRefPubMedPubMedCentral

110.

Brunet P, Gondouin B, Duval-Sabatier A et al (2011) Does uremia cause vascular dysfunction? Kidney Blood Press Res 34:284–290. https://doi.org/10.1159/000327131CrossRefPubMed

111.

Savira F, Magaye R, Hua Y et al (2019) Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy. Toxicol Lett 308:34–49. https://doi.org/10.1016/j.toxlet.2019.03.002CrossRefPubMed

112.

McCullough PA, Ronco C (2021) Textbook of cardiorenal medicine. Springer International Publishing, ChamCrossRef

113.

Gaikwad AB, Sayyed SG, Lichtnekert J et al (2010) Renal failure increases cardiac histone H3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol 176:1079–1083. https://doi.org/10.2353/ajpath.2010.090528CrossRefPubMedPubMedCentral

114.

Awad S, Al-Haffar KMA, Marashly Q et al (2015) Control of histone H3 phosphorylation by CaMKII. in response to haemodynamic cardiac stress. J Pathol 235:606–618. https://doi.org/10.1002/path.4489CrossRefPubMed

115.

Beckerman P, Ko YA, Susztak K (2014) Epigenetics: a new way to look at kidney diseases. Nephrol Dial Transplant 29:1821–1827. https://doi.org/10.1093/ndt/gfu026CrossRefPubMedPubMedCentral

116.

Bartel DP (2004) MicroRNAs Cell 116:281–297. https://doi.org/10.1016/S0092-8674(04)00045-5CrossRefPubMed

117.

Borges FT, Reis LA, Schor N (2013) Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Brazilian J Med Biol Res 46:824–830. https://doi.org/10.1590/1414-431X20132964CrossRef

118.

Medeiros T, Myette RL, Almeida JR et al (2020) Extracellular vesicles: cell-derived biomarkers of glomerular and tubular injury. Cell Physiol Biochem 54:88–109. https://doi.org/10.33594/000000207

119.

Salih M, Zietse R, Hoorn EJ (2014) Urinary extracellular vesicles and the kidney: biomarkers and beyond. Am J Physiol Physiol 306:F1251–F1259. https://doi.org/10.1152/ajprenal.00128.2014CrossRef

120.

De S, Kuwahara S, Hosojima M et al (2017) Exocytosis-mediated urinary full-length megalin excretion is linked with the pathogenesis of diabetic nephropathy. Diabetes 66:1391–1404. https://doi.org/10.2337/db16-1031CrossRefPubMed

121.

Huang CK, Bär C, Thum T (2020) miR-21, mediator, and potential therapeutic target in the cardiorenal syndrome. Front Pharmacol 11. https://doi.org/10.3389/fphar.2020.00726

122.

Thum T, Gross C, Fiedler J et al (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980–984. https://doi.org/10.1038/nature07511CrossRefPubMed

123.

Hinkel R, Ramanujam D, Kaczmarek V et al (2020) AntimiR-21 prevents myocardial dysfunction in a pig model of ischemia/reperfusion injury. J Am Coll Cardiol 75:1788–1800. https://doi.org/10.1016/j.jacc.2020.02.041CrossRefPubMed

124.

Rana I, Kompa AR, Skommer J et al (2015) Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiol Rep 3:e12371. https://doi.org/10.14814/phy2.12371

125.

Godwin JG, Ge X, Stephan K et al (2010) Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci 107:14339–14344. https://doi.org/10.1073/pnas.0912701107CrossRefPubMedPubMedCentral

126.

Eulalio A, Mano M, Ferro MD et al (2012) Functional screening identifies miRNAs inducing cardiac regeneration. Nature 492:376–381. https://doi.org/10.1038/nature11739CrossRefPubMed

127.

Corsten MF, Dennert R, Jochems S et al (2010) Circulating MicroRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3:499–506. https://doi.org/10.1161/CIRCGENETICS.110.957415CrossRefPubMed

128.

Goren Y, Kushnir M, Zafrir B et al (2012) Serum levels of microRNAs in patients with heart failure. Eur J Heart Fail 14:147–154. https://doi.org/10.1093/eurjhf/hfr155CrossRefPubMed

129.

Tijsen AJ, Creemers EE, Moerland PD et al (2010) MiR423-5p as a circulating biomarker for heart failure. Circ Res 106:1035–1039. https://doi.org/10.1161/CIRCRESAHA.110.218297CrossRefPubMed

130.

van Rooij E, Sutherland LB, Thatcher JE et al (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci 105:13027–13032. https://doi.org/10.1073/pnas.0805038105CrossRefPubMedPubMedCentral

131.

Han M, Toli J, Abdellatif M (2011) MicroRNAs in the cardiovascular system. Curr Opin Cardiol 26:181–189. https://doi.org/10.1097/HCO.0b013e328345983dCrossRefPubMed

132.

Tian Z, Greene AS, Pietrusz JL et al (2008) MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 18:404–411. https://doi.org/10.1101/gr.6587008CrossRefPubMedPubMedCentral

133.

Kato M, Zhang J, Wang M et al (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104:3432–3437. https://doi.org/10.1073/pnas.0611192104CrossRefPubMedPubMedCentral

134.

Wu J, Zheng C, Fan Y et al (2014) Downregulation of MicroRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol 25:92–104. https://doi.org/10.1681/ASN.2012111101CrossRefPubMed

135.

Liu Z, Wang S, Mi Q-S, Dong Z (2016) MicroRNAs in pathogenesis of acute kidney injury. Nephron 134:149–153. https://doi.org/10.1159/000446551CrossRefPubMed

136.

Rubinstein J, Sanford D (2019) Treatment of cardiorenal syndrome. Cardiol Clin 37:267–273. https://doi.org/10.1016/j.ccl.2019.04.002CrossRefPubMed

137.

Hoorn EJ, Ellison DH (2017) Diuretic resistance. Am J Kidney Dis 69:136–142. https://doi.org/10.1053/j.ajkd.2016.08.027CrossRefPubMed

138.

Cohen L (2014) The cardiorenal syndrome: pathophysiologic crosstalk, outcomes, and treatment targets. Cardiovasc Hematol Disord Targets 14:170–176. https://doi.org/10.2174/1871529X14666140701100913CrossRef

139.

Rangaswami J, Bhalla V, Blair JEA et al (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association Circulation 139. https://doi.org/10.1161/CIR.0000000000000664

140.

Cowger JA, Radjef R (2018) Advanced heart failure therapies and cardiorenal syndrome. Adv Chronic Kidney Dis 25:443–453. https://doi.org/10.1053/j.ackd.2018.08.012CrossRefPubMed

141.

Kim CS (2013) Pharmacologic management of the cardio-renal syndrome. Electrolytes Blood Press 11:17. https://doi.org/10.5049/EBP.2013.11.1.17CrossRef

142.

Testani JM, Coca SG, McCauley BD et al (2011) Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail 13:877–884. https://doi.org/10.1093/eurjhf/hfr070CrossRefPubMedPubMedCentral

143.

Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487–1491. https://doi.org/10.1161/01.CIR.0000159340.93220.E4CrossRefPubMed

144.

O’Connor CM, Starling RC, Hernandez AF et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32–43. https://doi.org/10.1056/NEJMoa1100171CrossRefPubMed

145.

Oliver E, Mayor F Jr, D’Ocon P (2019) Beta-blockers: historical perspective and mechanisms of action. Rev Española Cardiol English Ed 72:853–862. https://doi.org/10.1016/j.rec.2019.04.006

146.

Cagnoni F (2010) Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag 549. https://doi.org/10.2147/VHRM.S11816

147.

Pacurari M, Kafoury R, Tchounwou PB, Ndebele K (2014) The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam 2014:1–13. https://doi.org/10.1155/2014/689360CrossRef

148.

Takahama H, Kitakaze M (2017) Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets. Am J Physiol Circ Physiol 313:H715–H721. https://doi.org/10.1152/ajpheart.00215.2017CrossRef

149.

Ronco C (2017) The rise of expanded hemodialysis. Blood Purif 44:I–VIII. https://doi.org/10.1159/000476012

150.

Wolley MJ, Hutchison CA (2018) Large uremic toxins: an unsolved problem in end-stage kidney disease. Nephrol Dial Transplant 33:iii6–iii11. https://doi.org/10.1093/ndt/gfy179

151.

Sevinc M, Hasbal NB, Yilmaz V et al (2020) Comparison of circulating levels of uremic toxins in hemodialysis patients treated with medium cut-off membranes and high-flux membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) Randomized Control Study. Blood Purif 49:733–742. https://doi.org/10.1159/000508061CrossRefPubMed

Titel: Cardiorenal syndrome: long road between kidney and heart
verfasst von: Carolina Victoria Cruz Junho
Mayra Trentin-Sonoda
Karine Panico
Raquel Silva Neres dos Santos
Mariana Vieira Abrahão
Imara Caridad Stable Vernier
Cristina Ribas Fürstenau
Marcela Sorelli Carneiro-Ramos
Publikationsdatum: 08.02.2022
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 6/2022
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-022-10218-w

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cardiorenal syndrome: long road between kidney and heart

Abstract

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here

Atrial fibrillation-induced tachycardiomyopathy and heart failure: an underappreciated and elusive condition

Discussion of LBBP synchronization effects in HF patients with LBBB and comparison with BiV-CRT

Cardiovascular disease associated with methamphetamine use: a review

Soluble ST2: a valuable prognostic marker in heart failure

Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review

Neu im Fachgebiet Kardiologie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Darf man die Behandlung eines Neonazis ablehnen?

Update Kardiologie